Theratechnologies Inc. (NASDAQ:THTX) Q3 2023 Earnings Conference Call September 26, 2023 8:30 AM ET
Company Participants
John Mullaly - Investor Relations
Paul Levesque - President and Chief Executive Officer
Philip Dubuc - Senior Vice President and Chief Financial Officer
John Leasure - Global Commercial Officer
Christian Marsolais - Senior Vice President and Chief Medical Officer
Conference Call Participants
Justin Walsh - JonesTrading
Andre Uddin - Research Capital
Endri Leno - National Bank
Operator
Good day, and welcome to the Theratechnologies Q3 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.
I would now like to turn the conference over to John Mullaly. Please go ahead.
John Mullaly
Thank you, operator, and good morning, everyone.
On the call today will be Theratechnologies' President and Chief Executive Officer, Mr. Paul Levesque; and Senior Vice President and Chief Financial Officer, Mr. Philip Dubuc. During the Q&A session, we'll be joined by Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer; and Mr. John Leasure, the company's Global Commercial Officer.
Before we begin, I'd like to remind everyone that remarks today contain forward-looking statements regarding the company's current and future plans, expectations and intentions with respect to future events. Forward-looking statements are based on assumptions, and there are risks that results obtained by Theratechnologies may differ materially from those statements. As such, the company cannot guarantee any forward-looking statements will materialize, and you are cautioned not to place undue reliance on them.
The company refers current and potential investors to the forward-looking information section of Theratechnologies' Management Discussion and Analysis issued this morning and available on SEDAR, www.sedarplus.ca, and on EDGAR at www.sec.gov. Forward-looking statements represent Theratechnologies' expectations as of this morning, September 26, 2023.
Additionally, today, the company is using the term adjusted EBITDA, which is not a financial measure under International Financial Reporting Standards, IFRS, or U.S. Generally Accepted Accounting Principles, U.S. GAAP. Adjusted EBITDA excludes the effects of items that primarily reflect the impact of long-term investments and financing decisions rather than the results of day-to-day operations. Theratechnologies believes that this measure can be a useful indicator of its operational performance and financial condition from one period to another. The company uses this non-IFRS measure to make financial, strategic and operating decisions. Reconciliation of adjusted EBITDA to net loss is found in our MD&A issued this morning, available on SEDAR and on EDGAR at the web addresses mentioned earlier.